Q-omics provides the consensus-scored TMEM101 profile across patient tissues and cancer cell-line models. TMEM101 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TMEM101 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, TMEM101 RNA expression shows 18,339 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, LIHC, and ACC as cancer lineages where TMEM101 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM101 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM101 survival associations across molecular data types. TMEM101 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM101 RNA expression–survival associations across cancer types. High TMEM101 expression shows unfavorable associations in HNSC, LIHC, ACC and MESO, but favorable associations in BRCA and UVM. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TMEM101 RNA expression.
This table summarizes TMEM101 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM101. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM101 shows higher tumor expression in LIHC, BLCA, COAD, HNSC, CHOL and KICH. The LIHC box plot shows higher TMEM101 RNA expression in tumor versus normal tissue (log2 FC = +1.414, t-test p < 0.001).
This table shows molecular features associated with TMEM101 in patient tissues and cancer cell lines. In patient samples, TMEM101 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM101 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
